Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeting ornithine decarboxylase for the prevention of nonmelanoma skin cancer in humans.

Literature DB >> 20051367

Targeting ornithine decarboxylase for the prevention of nonmelanoma skin cancer in humans.

Abstract

Bailey et al. report in this issue of the journal (beginning on page 35) one of the first successful trials of basal cell carcinoma (BCC) prevention. Oral alpha-difluoromethyl-dl-ornithine (DFMO) reduced new BCCs in patients with a prior history of nonmelanoma skin cancer. DFMO is an inhibitor of ornithine decarboxylase, a key enzyme in the polyamine biosynthetic pathway. This perspective on Bailey et al. discusses our knowledge of the contribution of polyamines to BCC pathogenesis, how this knowledge advanced the development of a new method to prevent BCCs, and prospects for future studies of DFMO in BCC prevention.

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：
Ornithine Decarboxylase

Year: 2010 PMID： 20051367 PMCID： PMC2926793 DOI： 10.1158/1940-6207.CAPR-09-0248

Source DB: PubMed Journal: Cancer Prev Res (Phila) ISSN： 1940-6215

39 in total

1. Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice.

Authors: Jean Y Tang; Michelle Aszterbaum; Mohammad Athar; Franco Barsanti; Carol Cappola; Nini Estevez; Jennifer Hebert; Jimmy Hwang; Yefim Khaimskiy; Arianna Kim; Ying Lu; Po-Lin So; Xiuwei Tang; Michael A Kohn; Charles E McCulloch; Levy Kopelovich; David R Bickers; Ervin H Epstein
Journal: Cancer Prev Res (Phila) Date: 2010-01

Review 2. Does chronic sunscreen use reduce vitamin D production to insufficient levels?

Authors: M Norval; H C Wulf
Journal: Br J Dermatol Date: 2009-06-04 Impact factor: 9.302

3. Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine.

Authors: D S Alberts; R T Dorr; J G Einspahr; M Aickin; K Saboda; M J Xu; Y M Peng; R Goldman; J A Foote; J A Warneke; S Salasche; D J Roe; G T Bowden
Journal: Cancer Epidemiol Biomarkers Prev Date: 2000-12 Impact factor: 4.254

4. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study.

Authors: C Ulrich; J S Jürgensen; A Degen; M Hackethal; M Ulrich; M J Patel; J Eberle; D Terhorst; W Sterry; E Stockfleth
Journal: Br J Dermatol Date: 2009-11 Impact factor: 9.302

5. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer.

Authors: Howard H Bailey; KyungMann Kim; Ajit K Verma; Karen Sielaff; Paul O Larson; Stephen Snow; Theresa Lenaghan; Jaye L Viner; Jeff Douglas; Nancy E Dreckschmidt; Mary Hamielec; Marcy Pomplun; Harry H Sharata; David Puchalsky; Eric R Berg; Thomas C Havighurst; Paul P Carbone
Journal: Cancer Prev Res (Phila) Date: 2010-01

Review 6. Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma.

Authors: Nicholas F Evageliou; Michael D Hogarty
Journal: Clin Cancer Res Date: 2009-09-29 Impact factor: 12.531

7. Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival.

Authors: Jason A Zell; Argyrios Ziogas; Natalia Ignatenko; Jane Honda; Ning Qu; Alexander S Bobbs; Susan L Neuhausen; Eugene W Gerner; Hoda Anton-Culver
Journal: Clin Cancer Res Date: 2009-09-29 Impact factor: 12.531

8. Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.

Authors: Christine E McLaren; Sharon Fujikawa-Brooks; Wen-Pin Chen; Daniel L Gillen; Daniel Pelot; Eugene W Gerner; Frank L Meyskens
Journal: Cancer Prev Res (Phila) Date: 2008-12

9. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.

Authors: Frank L Meyskens; Christine E McLaren; Daniel Pelot; Sharon Fujikawa-Brooks; Philip M Carpenter; Ernest Hawk; Gary Kelloff; Michael J Lawson; Jayashri Kidao; John McCracken; C Gregory Albers; Dennis J Ahnen; D Kim Turgeon; Steven Goldschmid; Peter Lance; Curt H Hagedorn; Daniel L Gillen; Eugene W Gerner
Journal: Cancer Prev Res (Phila) Date: 2008-06

10. Spermine synthase deficiency leads to deafness and a profound sensitivity to alpha-difluoromethylornithine.

Authors: Xiaojing Wang; Snezana Levic; Michael Anne Gratton; Karen Jo Doyle; Ebenezer N Yamoah; Anthony E Pegg
Journal: J Biol Chem Date: 2008-11-10 Impact factor: 5.157

15 in total

1. Nonsurgical innovations in the treatment of nonmelanoma skin cancer.

Authors: Sadegh Amini; Martha H Viera; Whitney Valins; Brian Berman
Journal: J Clin Aesthet Dermatol Date: 2010-06

Review 2. Polyamines and cancer: implications for chemotherapy and chemoprevention.

Authors: Shannon L Nowotarski; Patrick M Woster; Robert A Casero
Journal: Expert Rev Mol Med Date: 2013-02-22 Impact factor: 5.600

3. Cytoplasmic accumulation of the RNA-binding protein HuR stabilizes the ornithine decarboxylase transcript in a murine nonmelanoma skin cancer model.

Authors: Shannon L Nowotarski; Lisa M Shantz
Journal: J Biol Chem Date: 2010-08-03 Impact factor: 5.157

Targeting ornithine decarboxylase for the prevention of nonmelanoma skin cancer in humans.

1. Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice.

Review 2. Does chronic sunscreen use reduce vitamin D production to insufficient levels?

3. Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine.

4. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study.

5. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer.

Review 6. Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma.

7. Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival.

8. Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.

9. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.

10. Spermine synthase deficiency leads to deafness and a profound sensitivity to alpha-difluoromethylornithine.

1. Nonsurgical innovations in the treatment of nonmelanoma skin cancer.

Review 2. Polyamines and cancer: implications for chemotherapy and chemoprevention.

3. Cytoplasmic accumulation of the RNA-binding protein HuR stabilizes the ornithine decarboxylase transcript in a murine nonmelanoma skin cancer model.

Review 4. Pathogenesis of nonmelanoma skin cancers in organ transplant recipients.

Review 5. Novel investigational drugs for basal cell carcinoma.

6. A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity.

7. Polyamine depletion inhibits the autophagic response modulating Trypanosoma cruzi infectivity.

8. Untargeted Metabolomics of Breast Cancer Cells MCF-7 and SkBr3 Treated With Tamoxifen/Trastuzumab.

9. Deciphering squamous cell carcinoma using multidimensional genomic approaches.

Review 10. Skin Carcinogenesis Studies Using Mouse Models with Altered Polyamines.